Law360, New York (January 13, 2012, 5:31 PM ET) -- Merck Canada Inc. on Friday sued Teva Pharmaceuticals USA Inc. in New Jersey federal court for allegedly infringing a Merck patent with its request for approval of a generic version of the asthma treatment Singulair.
Merck Canada, Merck Frosst Canada & Co. and Merck Sharp & Dohme Pharmaceuticals say they learned of Teva's plans to market a generic Singulair in a Nov. 29 letter notifying them of Teva's abbreviated new drug application with the U.S. Food and Drug Administration.
In the letter, Teva included a Paragraph...
Merck Unit Sues To Block Teva's Generic Singulair
To view the full article, take a free trial now.
